• Explore methods to determine and discuss prognosis with patients experiencing serious life-limiting illness.
• Appreciate demographic, psychosocial, and racial factors that are associated with decreased access to effective hospice and palliative care and recognize ways to promote a collaborative model of care that provides all patients with optimal serious illness care.
• Optimize ways to promote goal-concordant care and appreciate the suffering associated with insufficient goal-concordant care at end of life.
• Identify effective strategies to be utilized in collaboration with an interdisciplinary team to mitigate psychosocial suffering and facilitate adaptive coping in patients with serious life-limiting illness.
• Review new pharmacologic and non-pharmacologic management options available to palliate common symptoms associated with serious life-limiting illness.
• Outline protocols for transitioning patients from high-dose full opioid agonists to buprenorphine
• Appreciate the role of buprenorphine in managing OUD within palliative care
• Describe the use of IV buprenorphine in the inpatient setting
• Apply tips and tricks for successful buprenorphine use in the palliative care setting (with naloxone vs without, taste issues, patient counselling, etc.)
• Describe the pharmacology of buprenorphine
• List buprenorphine products that are FDA-approved for pain vs. addiction
• Appreciate the improved safety profile of buprenorphine over full opioid agonists
• Identify appropriate patients for buprenorphine
• Prescribe buprenorphine for patients who are opioid naive or on a relatively low dose of short-acting opioids.
• Apply tips and tricks for successful buprenorphine use in the palliative care setting (rash from adhesive, teaching specific to patch vs films, etc).

Attendance at any Mayo Clinic course does not indicate or guarantee competence or proficiency in the skills, knowledge or performance of any care or procedure(s) which may be discussed or taught in this course.